Tambotatug pelitecan

Antibody–drug conjugate

Also known as YL201, RG6919

Phase 3topline reported

Evidence outlook

Small Cell Lung Cancer: topline reported 2026-09-13

The sponsor reported topline results on 2026-09-13 (Phase 3 TAISHAN-302 (NCT06612151) met its overall survival primary endpoint at interim analysis). The announcement is listed under Regulatory events.

Latest reported trial: TAISHAN-302 (NCT06612151) · Phase 3 · met primary endpoint · grade pending

Also in development:Non-Small Cell Lung Cancer · Phase 1/2Nasopharyngeal Carcinoma · Phase 3Esophageal Squamous Cell Carcinoma · Phase 3Pancreatic Ductal Adenocarcinoma · Phase 3

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (5)
Esophageal Squamous Cell Carcinoma
Nasopharyngeal Carcinoma
Pancreatic Ductal Adenocarcinoma
Small Cell Lung Cancer
Phase 2 (1)
Other / comorbidity
NCT06241846 · MediLink Therapeutics (Suzhou) Co., Ltd.
2024-02-22 – 2029-02 · Metastatic Castration-resistant Prostate Cancer (mCRPC)
What this study did
Phase 1/2 (5)
Nasopharyngeal Carcinoma
NCT07258979 · MediLink Therapeutics (Suzhou) Co., Ltd.
2025-11-05 – 2028-05 · Recurrent or Metastatic Nasopharyngeal Carcinoma
What this study did
Non-Small Cell Lung Cancer
Small Cell Lung Cancer
NCT07407933 · MediLink Therapeutics (Suzhou) Co., Ltd.
2026-03-31 – 2029-02 · Thoracic Neoplasms, Lung Diseases, Small Cell Lung Carcinoma
What this study did
Other / comorbidity
NCT06057922 · MediLink Therapeutics (Suzhou) Co., Ltd.
2023-09-22 – 2028-10 · Advanced Solid Tumor
What this study did
NCT05434234 · MediLink Therapeutics (Suzhou) Co., Ltd.
2022-05-25 – 2027-10-06 · Advanced Solid Tumor
What this study did
Phase 1 (2)
Small Cell Lung Cancer
Other / comorbidity
NCT06394414 · MediLink Therapeutics (Suzhou) Co., Ltd.
2024-04-17 – 2030-04-29 · Advanced Solid Tumors
What this study did

Competitive landscape

6 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Esophageal Squamous Cell Carcinoma: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Tambotatug Pelitecan: this drugPhase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistnot yet gradedNo reviewed efficacy summary in this indication
NivolumabApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signal
NCT03189719: Primary endpoints, overall survival and progression-free survival: pembrolizumab plus cisplatin/fluorouracil improved both vs placebo plus chemotherapy; the label restricts use to PD-L1 CPS >=1, as an exploratory CPS <1 analysis showed OS HR 0.96 (KEYTRUDA label, KEYNOTE-590).
NCT02564263: Overall survival, pembrolizumab vs investigator's-choice chemotherapy: HR 0.70 (95% CI 0.52 to 0.94) in PD-L1 CPS >=10, HR 0.77 (0.63 to 0.96) in ESCC, HR 0.89 (0.75 to 1.05) in all randomized patients; the label approval is for ESCC with CPS >=10 (KEYTRUDA label, KEYNOTE-181).
TislelizumabApprovedMonoclonal antibodyPD-1Partial signal
NCT03957590: Progression-free Survival (PFS) (From randomization to the prespecified primary analysis data cut-off date of 08 January 2025; maximum time on study was 67 months.): Tislelizumab + Chemoradiotherapy 29 months | Placebo + Chemoradiotherapy 28.9 months missed
Ifinatamab DeruxtecanPhase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
Izalontamab BrengitecanPhase 3Antibody–drug conjugateEGFR + HER3not yet gradedNo reviewed efficacy summary in this indication
Risvutatug RezetecanPhase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
IzalontamabPhase 2Multispecific antibodyEGFR + HER3not yet gradedNo reviewed efficacy summary in this indication
ALE.P02Phase 1/2Antibody–drug conjugateClaudin-1 (CLDN1)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(12 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Tambotatug pelitecan to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (6)
January 2027 (1)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-01 · NCT07208773 · CT.gov ↗
What to watch
February 2027 (1)
Phase 2Metastatic Castration-resistant Prostate Cancer (mCRPC)Recruiting
Est. primary completion 2027-02 · NCT06241846 · CT.gov ↗
What to watch
April 2027 (2)
Phase 1/2Advanced Solid TumorRecruiting
Est. primary completion 2027-04-06 · NCT05434234 · CT.gov ↗
What to watch
Phase 1Advanced Solid TumorsActive not recruiting
Est. primary completion 2027-04-29 · NCT06394414 · CT.gov ↗
What to watch
December 2027 (2)
Phase 3Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-12-01 · NCT06612151 · CT.gov ↗
What to watch
Phase 3Nasopharyngeal CarcinomaActive not recruiting
Est. primary completion 2027-12-01 · NCT06629597 · CT.gov ↗
What to watch
2028 (3)
February 2028 (1)
Phase 1/2Nasopharyngeal CarcinomaRecruiting
Est. primary completion 2028-02 · NCT07258979 · CT.gov ↗
What to watch
April 2028 (1)
Phase 3Esophageal Squamous Cell CarcinomaRecruiting
Est. primary completion 2028-04-30 · NCT07487896 · CT.gov ↗
What to watch
November 2028 (1)
Phase 1/2Small Cell Lung CancerRecruiting
Est. primary completion 2028-11 · NCT07407933 · CT.gov ↗
What to watch
2029 (2)
January 2029 (1)
Phase 3Pancreatic Ductal AdenocarcinomaNot yet recruiting
Est. primary completion 2029-01 · NCT07803783 · CT.gov ↗
What to watch
June 2029 (1)
Phase 3Small Cell Lung CancerRecruiting
Est. primary completion 2029-06 · NCT07739758 · CT.gov ↗
What to watch
2031 (1)
June 2031 (1)
Phase 1Small Cell Lung CancerActive not recruiting
Est. primary completion 2031-06-23 · NCT06898957 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

13 September 2026Topline resultPhase 3 TAISHAN-302 (NCT06612151) met its overall survival primary endpoint at interim analysis
MediLink Therapeutics (reported by its collaborator Roche) · Source ↗